Charles J Lockwood Selected Research

hI-con1

10/2011	Tissue factor expression in ovarian cancer: implications for immunotherapy with hI-con1, a factor VII-IgGF(c) chimeric protein targeting tissue factor.
6/2011	Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Charles J Lockwood Research Topics

Disease

23	Pre-Eclampsia (Preeclampsia) 12/2023 - 03/2005
20	Hemorrhage 12/2017 - 09/2002
15	Inflammation (Inflammations) 12/2023 - 03/2004
12	Uterine Hemorrhage (Uterine Bleeding) 06/2023 - 09/2002
11	Endometriosis 01/2021 - 04/2008
9	Infections 01/2022 - 02/2006
9	Rupture 01/2020 - 12/2004
9	Premature Birth (Birth, Premature) 01/2020 - 11/2003
8	Hypoxia (Hypoxemia) 03/2015 - 09/2002
7	Chorioamnionitis 12/2015 - 09/2005
7	Thrombophilia 03/2011 - 02/2002
6	Preterm Premature Rupture of the Membranes 01/2020 - 07/2005
5	Abruptio Placentae (Placental Abruption) 01/2016 - 09/2005
4	Neoplasms (Cancer) 01/2020 - 02/2010
4	Fetal Growth Retardation (Intrauterine Growth Retardation) 11/2015 - 02/2007
2	COVID-19 01/2022 - 11/2021
2	Thrombosis (Thrombus) 01/2022 - 02/2002
2	Infertility (Sterility) 03/2018 - 04/2012
2	Stillbirth 01/2018 - 09/2010
2	Macular Degeneration (Age-Related Maculopathy) 02/2017 - 02/2010
2	Ischemia 01/2016 - 03/2004
2	Major Depressive Disorder (Major Depressive Disorders) 09/2012 - 11/2011
2	Proteinuria 07/2008 - 05/2006
2	Thromboembolism 09/2007 - 02/2002
2	Premature Obstetric Labor (Premature Labor) 04/2007 - 06/2006
2	Activated Protein C Resistance (APC Resistance) 02/2004 - 12/2003
2	Hyperhomocysteinemia 02/2004 - 02/2002
1	Adenomyosis 11/2023
1	Pregnancy Complications 01/2022
1	Leiomyoma (Uterine Fibroids) 01/2022
1	Cytokine Release Syndrome 01/2022

Drug/Important Bio-Agent (IBA)

29	Thrombin FDA Link 06/2023 - 09/2002
18	CytokinesIBA 01/2022 - 08/2005
17	Progestins (Progestagens)IBA 06/2023 - 09/2002
15	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 01/2019 - 12/2003
14	Thromboplastin (Tissue Factor)IBA 06/2023 - 07/2005
12	Proteins (Proteins, Gene)FDA Link 01/2022 - 09/2002
11	Contraceptive Agents (Contraceptives)IBA 06/2023 - 09/2002
9	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 02/2017 - 09/2002
8	Messenger RNA (mRNA)IBA 11/2023 - 09/2002
8	Progesterone FDA LinkGeneric 01/2016 - 03/2004
7	Interleukin-8 (Interleukin 8)IBA 06/2023 - 03/2004
7	Matrix Metalloproteinases (MMPs)IBA 01/2016 - 07/2005
7	Interleukin-1beta (Interleukin 1 beta)IBA 08/2009 - 02/2006
6	ChemokinesIBA 01/2022 - 11/2010
5	Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)IBA 01/2020 - 05/2009
5	Plasminogen Activator Inhibitor 1IBA 01/2016 - 11/2005
5	Hemostatics (Antihemorrhagics)IBA 04/2011 - 08/2005
4	Interleukin-6 (Interleukin 6)IBA 12/2023 - 06/2008
4	InterferonsIBA 01/2019 - 09/2014
4	Factor VII (Proconvertin)IBA 06/2011 - 03/2004
3	Small Interfering RNA (siRNA)IBA 11/2023 - 10/2011
3	Interleukin-11 (Interleukin 11)IBA 01/2022 - 09/2005
3	SteroidsIBA 01/2022 - 09/2002
3	Immunoconjugates (Immunoconjugate)IBA 12/2020 - 02/2010
3	Prothrombin (Factor II)IBA 06/2017 - 02/2002
3	Progesterone Receptors (Progesterone Receptor)IBA 01/2016 - 02/2008
3	Chemokine CCL2 (Monocyte Chemoattractant Protein 1)IBA 06/2012 - 02/2006
3	Heparin (Liquaemin)FDA LinkGeneric 12/2011 - 02/2002
3	Reactive Oxygen Species (Oxygen Radicals)IBA 04/2011 - 09/2002
3	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 08/2009 - 03/2005
2	Medroxyprogesterone Acetate (Depo-Provera)FDA LinkGeneric 11/2023 - 09/2002
2	EnzymesIBA 01/2021 - 01/2019
2	MicroRNAs (MicroRNA)IBA 01/2020 - 02/2016
2	Interleukin-1 (Interleukin 1)IBA 01/2019 - 11/2010
2	Toll-Like Receptors (Toll-Like Receptor)IBA 01/2019 - 01/2016
2	RNA (Ribonucleic Acid)IBA 01/2018 - 02/2016
2	GlucocorticoidsIBA 12/2016 - 01/2015
2	Proteinase-Activated ReceptorsIBA 01/2016 - 09/2011
2	tiboloneIBA 05/2015 - 11/2005
2	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 06/2012 - 09/2011
2	Tyrosine (L-Tyrosine)FDA Link 12/2011 - 04/2007
2	Antiphospholipid AntibodiesIBA 11/2011 - 09/2010
2	hI-con1IBA 10/2011 - 06/2011
2	A-factor (Streptomyces)IBA 10/2011 - 06/2011
2	Angiopoietin-2IBA 04/2011 - 02/2009
2	Vascular Endothelial Growth Factor Receptor-1 (fms-Like Tyrosine Kinase)IBA 07/2009 - 03/2005
2	Angiopoietin-1IBA 02/2009 - 09/2002
2	CreatinineIBA 07/2008 - 05/2006
2	Plasminogen InactivatorsIBA 04/2007 - 02/2002
2	Peptide Hydrolases (Proteases)FDA Link 02/2007 - 11/2005
2	Levonorgestrel (Plan B)FDA LinkGeneric 03/2004 - 11/2003
2	AnticoagulantsIBA 02/2004 - 02/2002
2	factor V LeidenIBA 02/2004 - 02/2002
1	LeptinIBA 12/2023
1	Carrier Proteins (Binding Protein)IBA 11/2023
1	Estradiol (Delestrogen)FDA LinkGeneric 11/2023
1	Leukemia Inhibitory FactorIBA 11/2023
1	Transcription Factors (Transcription Factor)IBA 11/2023
1	Cyclooxygenase 2 (Cyclooxygenase-2)IBA 06/2023
1	Viral RNAIBA 01/2022
1	RNA-Directed DNA Polymerase (Reverse Transcriptase)IBA 11/2021
1	2-hydroxyestradiolIBA 01/2021
1	4-hydroxyestradiolIBA 01/2021
1	Propranolol (Inderal)FDA LinkGeneric 01/2021
1	Cytochrome P-450 CYP1A1 (CYP1A1)IBA 01/2021
1	p38 Mitogen-Activated Protein KinasesIBA 01/2021

Therapy/Procedure

7	Therapeutics 02/2017 - 02/2002
4	Contraception (Birth Control) 01/2020 - 09/2002
2	Immunotherapy 10/2011 - 06/2011